Patent intelligence · US
US 11931402
Compositions for treating heart disease by inhibiting the action of mAKAP-β
Compositions for treating heart disease by inhibiting the action of mAKAP-β
Patent details — US 11931402
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 19, 2024
- Expiration
- Mar 14, 2044
- Applicant
- Anchored RSK3 Inhibitors, LLC
- Claims
- 17
- CPC classes
- A61K, A61K31/519, A61K31/7048, A61K31/713
Quick answer
US 11931402 (Compositions for treating heart disease by inhibiting the action of mAKAP-β) is held by Anchored RSK3 Inhibitors, LLC. Status: granted. Granted Mar 19, 2024. Expires Mar 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Anchored RSK3 Inhibitors, LLC
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/519, A61K31/7048, A61K31/713, A61K38/005, A61K38/1709
More from Anchored RSK3 Inhibitors, LLC
Related pharmaceutical patents in our USPTO index.
-
US 11229679
Compositions for treating heart disease by inhibiting the action of mAKAPβ
granted -
US 10617737
Compositions for treating heart disease by inhibiting the action of mAKAP-β
granted -
US 9937228
Treatment of myocardial infarction by inhibiting the action of mAKAPβ
granted -
US 9132174
Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
granted
Frequently asked questions
What is US patent 11931402?
US 11931402 (Compositions for treating heart disease by inhibiting the action of mAKAP-β) is held by Anchored RSK3 Inhibitors, LLC. Status: granted. Granted Mar 19, 2024. Expires Mar 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11931402?
Anchored RSK3 Inhibitors, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11931402 expire?
Our index shows an expiration date of Mar 14, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.